Journal Mobile Options
Table of Contents
Vol. 79, No. 5, 2004
Issue release date: 2004
Neuroendocrinology 2004;79:259–267
(DOI:10.1159/000079320)

17β-Estradiol Promotes Striatal Medium Size Spiny Neuronal Maturation in vitro

Stroppolo A. · Tian C. · Guinea B. · Olm V. · Sheffield R. · Sommer J. · Ehrlich M.E.
The Nathan Kline Institute, Orangeburg, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Gender differences exist in the development of the nigrostriatal dopamine system, and in the incidence and course of pediatric and adult neuropsychiatric diseases in which this system is implicated. The medium size spiny neuron (MSN) is the major output neuron of the caudate nucleus. It receives a large dopaminergic input from the substantia nigra, and 96% of the MSNs express DARPP-32, a dopamine and cyclic AMP-regulated phosphoprotein and key mediator of dopamine function. There are few examples, however, of direct effects of sex hormones, including 17β-estradiol (E2), on the MSN. We report that in vitro, E2 (10–50 nM) promotes MSN phenotypic maturation, as determined by increased soma size, neurite length, and DARPP-32 protein levels. Treatment with the ‘anti-estrogen’ ICI 182,780 or the partial-agonist tamoxifen also increases DARPP-32 levels, but when added to E2, ICI 182,780 only prevents the increase in DARPP-32 levels and increase in soma size and neurite length. Surprisingly, maturation effects are more robust in cells derived exclusively from female embryos. Western blot analysis of protein lysates and immunocytochemistry of cultured MSNs reveals the presence of the estrogen receptor β (ERβ). These data suggest that ERβ may mediate the differentiating effect of E2 on embryonic MSNs, and provide new avenues of investigation for the role of sex hormones in the development of the striatum and in diseases affecting the basal ganglia.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Andersen AL, Rutstein M, Benzo JM, Hostetter JC, Teicher MH: Sex differences in dopamine receptor overproduction and elimination. Neuroreport 1997;8:1495–1498.
  2. Andersen SL, Thompson AP, Krenzel E, Teicher MH: Pubertal changes in gonadal hormones do not underlie adolescent dopamine receptor overproduction. Psychoneuroendocrinology 2002;27:683–691.
  3. Floerke-Nashner LR, Burlingame LA, Berger-Sweeney J: Sex differences in neurogenesis in mouse striatum. Soc Neurosci Abstr 2000;30:224.9.
  4. Kurlan R: The pathogenesis of Tourette’s syndrome: A possible role for hormonal and excitatory neurotransmitter influences in brain development. Arch Neurol 1992;49:874–876.
  5. Kompoliti K: Estrogen and movement disorders. Clin Neuropharmacol 1999;22:318–326.
  6. Tsang KL, Ho SL, Lo SK: Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000;54:2292–2298.
  7. Becker JB, Molenda H, Hummer DL: Gender differences in the behavioral responses to cocaine and amphetamine. Implications for mechanisms mediating gender differences in drug abuse. Ann NY Acad Sci 2001;937:172–187.
  8. Euvrard C, Oberlander C, Boissier JR: Antidopaminergic effects of estrogens at the striatal level. J Pharmacol Exp Ther 1980;214:179–185.
  9. Becker JB: Direct effect of 17β-estradiol on striatum: Sex differences in dopamine release. Synapse 1990;5:157–164.
  10. Becker JB: Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 1999;64:803–812.
  11. Mermelstein PG, Becker JB, Surmeier DJ: Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J Neurosci 1996;16:595–604.
  12. Tansey EM, Arbuthnott GW, Fink G, Whale D: Oestradiol-17β increases the firing rate of antidromically identified neurons of the rat neostriatum. Neuroendocrinology 1983;37:106–110.
  13. Arnauld E, Dufy B, Pestre M, Vincent JD: Effects of estrogens on the response of caudate neurons to microiontophoretically applied dopamine. Neurosci Lett 1981;21:325–331.
  14. Maus M, Bertrand P, Drouva S, Rasolonjanahary R, Kordon C, Glowinski J, Premont J, Enjalbert A: Differential modulation of D1 and D2 dopamine-sensitive adenylate cyclases by 17β-estradiol in cultured striatal neurons and anterior pituitary cells. J Neurochem 1989;52:410–418.
  15. Lee SH, Mouradian MM: Up-regulation of D1A dopamine receptor gene transcription by estrogen. Mol Cell Endocrinol 1999;156:151–157.
  16. Zhou Y, Dorsa DM: Estrogen rapidly induces c-jun immunoreactivity in rat striatum. Horm Behav 1994;28:376–382.
  17. Hruska RE, Ludmer LM, Pitman KT, De Ryck M, Silbergeld EK: Effects of estrogen on striatal dopamine receptor function in male and female rats. Pharmacol Biochem Behav 1982;16:285–291.
  18. Hruska RE, Nowak MW: Estrogen treatment increases the density of D1 dopamine receptors in the rat striatum. Brain Res 1988;442:349–350.
  19. Ivkovic S, Ehrlich ME: Expression of the DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 1999;19:5409–5419.
  20. Greengard P: The neurobiology of slow synaptic transmission. Science 2001;294:1024–1030.
  21. Quimet CC, Langley-Gullion KC, Greengard P: Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res 1998;808:8–12.
  22. Nakao N, Brundin P, Funa K, Lindvall O, Odin P: Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro. Dev Brain Res 1995;90:92–101.
  23. Ivkovic S, Polonskaia O, Farinas I, Ehrlich ME: Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: Studies in vivo and in vitro. Neuroscience 1997;79:509–516.
  24. Ehrlich ME, Rosen NL, Kurihara T, Shalaby IA, Greengard P: DARPP-32 development in the caudate nucleus is independent of afferent input from the substantia nigra. Dev Brain Res 1990;54:257–263.
  25. Brewer GJ: Serum-free B27/Neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res 1995;42:674–683.
  26. Iacovitti L, Stull ND, Mishizen A: Neurotransmitters, KCl and antioxidants rescue striatal neurons from apoptotic cell death in culture. Brain Res 1999;816:276–285.
  27. Brewer GJ, Torricelli JR, Evege EK, Price PJ: Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 1993;35:567–576.
  28. Jones PS, Parrott E, White INH: Activation of transcription by estrogen receptor α and β cell type- and promoter-dependent. J Biol Chem 1999;274:32008–32014.
  29. Wade CB, Robinson S, Shapiro RA, Dorsa DM: Estrogen receptor (ER)α and ERβ exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 2001;142:2336–2342.
  30. Foster GA, Schultzberg M, Kokfelt T, Goldstein M, Hemmings HC Jr, Ouimet CC, Walaas SI, Greengard P: Ontogenity of the dopamine and cyclic adenosine-3′,5′-monophosphate-regulated phosphoprotein (DARPP-32) in the pre- and postnatal mouse central nervous system. Int J Dev Neurosci 1988;6:367–386.
  31. Gustafson E, Ehrlich ME, Trivedi P, Greengard P: Developmental regulation of phosphoprotein gene expression in the caudate putamen of rat: An in situ hybridization study. Neuroscience 1992;51:65–75.
  32. Graybiel A: Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244–254.
  33. Auger AP, Tetel MJ, McCarthy MM: Steroid receptor coactivator-1 (SRC-1) mediates the development of sex-specific brain morphology and behavior. Proc Natl Acad Sci USA 2000;97:7551–7555.
  34. McDonnell DP, Norris JD: Connections and regulation of the human estrogen receptor. Science 2002;296:1642–1644.
  35. Kuppers E, Beyer C: Expression of aromatase in the embryonic and postnatal mouse striatum. Mol Brain Res 1998;63:184–188.
  36. Foster WG, Chan S, Platt L, Hughes CL Jr: Detection of phytoestrogens in samples of second trimester human amniotic fluid. Toxicol Lett 2002;129:199–205.
  37. Toran-Allerand CD, Miranda RC, Hochberg RB, MacLusky NJ: Cellular variation in estrogen receptor mRNA translation in the developing brain. Brain Res 1992;576:25–41.
  38. Kuppers E, Beyer C: Expression of estrogen receptor-α and -β mRNA in the developing and adult mouse striatum. Neurosci Lett 1999;276:95–98.

    External Resources

  39. Shughrue P, Scrimo P, Lane M, Askew R, Merchenthaler I: The distribution of estrogen receptor-β mRNA in forebrain regions of the estrogen receptor-α knockout mouse. Endocrinology 1997;138:5649–5652.
  40. Shughrue PJ, Merchenthaler I: Distribution of estrogen receptor β immunoreactivity in the rat central nervous system. J Comp Neurol 2001;436:64–81.
  41. Mitra WM, Hoskin E, Yudkovitz J, Pear L, Wilkinson HA, Hayashi S, Pfaff DW, Ogawa S, Rohrer SP, Schaeffer JM, McEwen BS, Alves SE: Immunolocalization of estrogen receptor β in the mouse brain: Comparison with estrogen receptor α. Endocrinology 2003;144:2055–2067.
  42. Pfaff D, Keiner M: Atlas of estradiol-concentrating cells in the central nervous system of the rat. J Comp Neurol 1973;151:121–158.
  43. Laflamme N, Nappi RE, Drolet G, Labrie C, Rivest S: Expression and neuropeptidergic characterization of estrogen receptors (ERα and ERβ) throughout the rat brain: Anatomical evidence of distinct roles of each subtype. J Neurobiol 1998;36:357–378.
  44. Shughrue PJ, Stumpf WE, MacLusky NJ, Zielinski JE, Hochberg RB: Developmental changes in estrogen receptors in mouse cerebral cortex between birth and postweaning: Studied by autoradiography with 11β-methoxy-16α-[125I]iodoestradiol. Endocrinology 1990;126:1112–1124.
  45. Toran-Allerand CD, Guan X, MacLusky NJ, Horvath TL, Diano S, Singh M, Connolly ES Jr, Nethrapalli IS, Tinnikov AA: ER-X: A novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 2002;22:8391–8401.
  46. Sato K, Matsui N, Ohno Y, Nakazawa K: Effects of 17β-estradiol and xenoestrogens on the neuronal survival in an organotypic hippocampal culture. Neuroendocrinology 2002;76:223–234.
  47. Webb P, Lopez GN, Uht RM, Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443–456.
  48. Paech K, Webb P, Kuiper GGJM, Nilsson G, Gustafsson JA, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997;277:1508–1510.
  49. Shapiro RA, Xu C, Dorsa DM: Differential transcriptional regulation of rat vasopressin gene expression by estrogen receptor α and β. Endocrinology 2000;141:4056–4064.
  50. Becker JB: Oestrogen effects on dopaminergic function in striatum; in Neuronal and Cognitive Effects of Oestrogens. Novartis Found Symp 230. Chichester, Wiley, 2000, pp 134–151.
  51. Xiao L, Jackson LR, Becker JB: The effect of estradiol in the striatum is blocked by ICI 182,780 but not tamoxifen: Pharmacological and behavioural evidence. Neuroendocrinology 2003;77:239–245.
  52. Beyer C, Karolczak M: Estrogenic stimulation of neurite growth in midbrain dopaminergic neurons depends on cAMP/protein kinase A signalling. J Neurosci Res 2000;59:107–116.
  53. Lee D, Wang L, Dong P, Tran T, Copolov D, Lim AT: Progesterone modulation of D5 receptor expression in hypothalamic ANP neurons, the role of estrogen. Mol Psychiatry 2001;6:112–117.
  54. Stroppolo A, Guinea B, Tian C, Sommer J, Ehrlich ME: Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro. J Neurochem 2001;79:1027–1032.
  55. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538–541.
  56. Wang L, Andersson S, Warner M, Gustafsson JA: Morphological abnormalities in the brains of estrogen receptor β knockout mice. Proc Natl Acad Sci USA 2001;98:2792–2796.
  57. Dorling AA, Todman MG, Korach KS, Herbison AE: Critical role for estrogen receptor alpha in negative feedback regulation of gonadotropin-releasing hormone mRNA expression in the female mouse. Neuroendocrinology 2003;78:204–209.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50